345 related articles for article (PubMed ID: 16647451)
1. Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Rehm B; Keller F; Mayer J; Stracke S
Transplant Proc; 2006 Apr; 38(3):711-3. PubMed ID: 16647451
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
[TBL] [Abstract][Full Text] [Related]
3. Conversion to everolimus in maintenance patients--current clinical strategies.
Pohanka E
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
[TBL] [Abstract][Full Text] [Related]
4. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
Ruiz JC; Sanchez-Fructuoso A; Rodrigo E; Conesa J; Cotorruelo JG; Gómez-Alamillo C; Calvo N; Barrientos A; Arias M
Transplant Proc; 2006 Oct; 38(8):2424-6. PubMed ID: 17097956
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus-induced pneumonitis following liver transplantation.
Roberts RJ; Wells AC; Unitt E; Griffiths M; Tasker AD; Allison ME; Bradley JA; Watson CJ
Liver Transpl; 2007 Jun; 13(6):853-6. PubMed ID: 17539005
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
[TBL] [Abstract][Full Text] [Related]
7. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.
De Simone P; Petruccelli S; Precisi A; Carrai P; Doria R; Menichetti F; Filipponi F
Transplant Proc; 2007 Dec; 39(10):3500-1. PubMed ID: 18089420
[TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
[TBL] [Abstract][Full Text] [Related]
10. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
13. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus conversion experience in a single center.
Wang HH; Huang JY; Chu SH; Chiang YJ; Liu KL; Lai PC
Transplant Proc; 2008 Sep; 40(7):2209-10. PubMed ID: 18790194
[TBL] [Abstract][Full Text] [Related]
15. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
16. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors.
Morath C; Schwenger V; Ksoll-Rudek D; Sommerer C; Beimler J; Schmidt J; Zeier M
Transplant Proc; 2007; 39(1):99-102. PubMed ID: 17275483
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-related pulmonary toxicity in heart transplant recipients.
Expósito V; de Prada JA; Gómez-Román JJ; González-Vilchez F; Llano-Cardenal M; García-Camarero T; Fernández-Valls M; Ruano J; Martín-Durán R
J Heart Lung Transplant; 2008 Jul; 27(7):797-800. PubMed ID: 18582812
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
20. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.
Weiner SM; Sellin L; Vonend O; Schenker P; Buchner NJ; Flecken M; Viebahn R; Rump LC
Nephrol Dial Transplant; 2007 Dec; 22(12):3631-7. PubMed ID: 17611248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
